Features | Partner Sites | Information | LinkXpress
Sign In
Fluke Biomedical
Schiller
Ampronix

High Blood Pressure May Be More Dangerous for Women

By HospiMedica International staff writers
Posted on 13 Jan 2014
A new study has identified significant differences in the mechanisms that cause high blood pressure in women, as compared to men.

Researchers at Wake Forest Baptist Medical Center (Winston-Salem, NC, USA) conducted a study involving 100 men and women age 53 and older (39% women) with untreated high blood pressure and no other major diseases. The researchers then utilized noninvasive impedance cardiography, applanation tonometry, and plasma measures of angiotensin II, angiotensin (1–7), serum aldosterone, high-sensitivity C-reactive protein (hs-CRP), and cytokine biomarkers of inflammation to characterize the hemodynamic and hormonal profile of the patients.

The results showed that despite there being no differences between women and men in terms of office blood pressure, heart rate, and body mass index (BMI), men demonstrated lower values of pulse pressure, systemic vascular resistance, brachial artery pulse wave velocity and augmentation index. In all, women had 30%–40% more vascular disease than men for the same level of elevated blood pressure. In addition, there were significant physiologic and hormonal differences in the women's cardiovascular system that contributed to the severity and frequency of heart disease.

In each of the hypertension categories, the increased blood pressure in men was associated with significant augmentations in stroke volume and cardiac output compared with women. Sex-related hemodynamic differences were associated in women with higher plasma levels of leptin, hs-CRP, plasma angiotensin II and serum aldosterone, and no differences in the serum concentrations of cytokinins. The study was published in the December 2013 issue of Therapeutic Advances in Cardiovascular Disease.

“The medical community thought that high blood pressure was the same for both sexes and treatment was based on that premise,” said lead author professor Carlos Ferrario, MD. “This is the first study to consider sex as an element in the selection of antihypertensive agents or base the choice of a specific drug on the various factors accounting for the elevation in blood pressure.”

“Our study findings suggest a need to better understand the female sex-specific underpinnings of the hypertensive processes to tailor optimal treatments for this vulnerable population,” added Dr. Ferrario. “We need to evaluate new protocols–what drugs, in what combination, and in what dosage—to treat women with high blood pressure.”

Related Links:

Wake Forest Baptist Medical Center



Centurion Service
Bovie Medical
MinXray

Channels

Critical Care

view channel
Image: The Trellis peripheral infusion system (Photo courtesy of Covidien).

Thrombolytic Drug Delivery Device Dissolves Blood Clots

A redesigned peripheral infusion system enables focused treatment of blood clots to avoid potential post-thrombotic syndrome (PTS). The updated Trellis peripheral infusion system is a pharmacomechanical... Read more

Surgical Techniques

view channel
Image: The Optimis Fusion integrated laser platform (Photo courtesy of Quantel Medical).

Combination Laser Platform Treats Glaucoma and Cataract

An integrated laser offers ophthalmologists a versatile armamentarium for treating both cataract and glaucoma in an efficient combination platform. The Optimis Fusion integrated laser combines advanced... Read more

Health IT

view channel

Wikipedia Dominates Internet Drug Information

Wikipedia, along with Google and WebMD, is where more than half of all Americans turn to for health information on prescription drugs. Researchers at the Blackstone Group (London, United Kingdom), Harvard Medical School (Boston, MA, USA), and other institutions selected new drug-safety communications related to prescription... Read more

Business

view channel

Spectranetics Completes Acquisition of AngioScore

Spectranetics (Colorado Springs, CO, USA) has completed the acquisition of AngioScore (Fremont, CA, USA), a leading developer, manufacturer, and marketer of cardiovascular specialty balloons. The transaction, for USD 230 million in cash and contingent commercial and regulatory milestone payments, will combine differentiated,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.